Industry News

Amgen today announced positive top-line results for erenumab from A Phase 3, R andom I zed, double-blind, placebo-controlled S tudy to E valuate the efficacy and safety of erenumab in migraine prevention. These data showed the ARISE study met the primary endpoint, demonstrating a statistically significant reduction from baseline in monthly migraine days in patients with episodic migraine treated with erenumab compared with..."/>
Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study
Catabasis Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, today announced the closing of an underwritten offering of 2,875,000 shares of its common stock, including 375,000 shares purchased by the underwriter pursuant to the exercise in full of its option to purchase additional shares, at a price of $4.00 per share. Catabasis received gross proceeds of $11.5 million, before deducting underwriting discounts and commissions and other..."/>
Catabasis Pharmaceuticals Announces Closing of $11.5 Million Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
Enanta Pharmaceuticals, Inc.,, a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has initiated a Phase 1 clinical study and has begun dosing healthy adults with EDP-305, Enanta’ s lead farnesoid X..."/>
Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-305, its Lead FXR Agonist for the Treatment of Non-alcoholic Steatohepatitis (NASH)
Merrimack Pharmaceuticals, Inc. today announced it will present six posters from its systems-biology derived antibody engineering and nanotherapeutic portfolios at the European Society for Medical Oncology 2016 Congress, October 7– 11, 2016 in Copenhagen, Denmark. Merrimack will present the final results of the Phase 3 NAPOLI-1 study in a poster discussion session and a NAPOLI-1 safety-over-time subset analysis in a separate..."/>
Merrimack to Present Final Results of Phase 3 NAPOLI-1 Study at the European Society for Medical Oncology 2016 Congress
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that Japan’ s Ministry of Health, Labor& Welfare has approved JUXTAPID for patients with homozygous familial hypercholesterolemia.. HoFH is a serious, rare genetic disease that impairs the function of the receptor responsible for removing LDL-C..."/>
Aegerion Pharmaceuticals’ JUXTAPID® (lomitapide) Capsules Approved in Japan for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced the distribution of TREXIMET ® 10/ 60 mg to wholesalers has begun. TREXIMET 10/ 60 mg is indicated for use in pediatric patients 12 years of age and older for the acute treatment of migraine with or without aura. ¹ TREXIMET received U.S. Food and Drug Administration approval for use in the pediatric population 12 years of age..."/>
Pernix Therapeutics Announces Distribution of TREXIMET® 10/60 mg (sumatriptan 10mg and naproxen sodium 60 mg) Dose For Use in Pediatric Patients
Intra-Cellular Therapies, Inc. today announced top-line results from the second Phase 3 clinical trial of ITI-007, an oral, first-in-class investigational medicine for the treatment of schizophrenia. In this trial, neither dose of ITI-007 separated from placebo on the primary endpoint, change from baseline on the Positive and Negative Syndrome Scale total score, in the pre-defined patient population. The active control, risperidone, did separate from..."/>
Intra-Cellular Therapies Announces Top-Line Results from the Second Phase 3 Trial of ITI-007 in Patients with Schizophrenia (Study ‘302)
Genmab A/S. Copenhagen, Denmark; September 28, 2016- Genmab A/S announces under reference to Section 29 of the Danish Securities Trading Act that Baillie Gifford& Co has corrected their previous notification of September 22, 2016."/>
Major Shareholder Announcement
Tactile Systems Technology of northeast Minneapolis has been a winner for shareholders since it went public in July at a price of $10 per share. The fast-growing medical products company, which does business as Tactile Medical, raised more than $40 million in its offering. The stock closed Friday at $20.18 per share, a nearly doubling of shareholder value to more than $320 million."/>
IPO market remains a shadow of its former self [Star Tribune (Minneapolis)]
Medtronic's MiniMed 670 G hybrid closed looped system, the first FDA-approved device that is intended to automatically monitor glucose and provide appropriate basal insulin doses in people 14 years of age and older with type 1 diabetes. The human pancreas naturally supplies a low, continuous rate of insulin, known as basal or background insulin."/>
FDA approves first automated insulin delivery device for type 1 diabetes
Hill-Rom Holdings, Inc., a global medical technology company, today announced its commitment to add over 100 new jobs at its Welch Allyn subsidiary's facilities in Skaneateles Falls, NY. The commitment, which will bring additional manufacturing, marketing and research and development jobs to the area, comes one year after Hill-Rom acquired Welch Allyn, which is based in Central New York and has maintained a significant presence..."/>
Hill-Rom Adding More Than 100 Jobs In Central New York
Thermo Fisher Scientific and Dr. Schar USA Inc. have awarded Wake Forest Baptist Medical Center in Winston-Salem, North Carolina a $20,000 grant to help fund a one-day family screening event on Saturday, October 22, 2016 where biological relatives of celiac disease patients will be offered free blood testing. Celiac disease is a serious autoimmune condition with a genetic component, affecting just under one percent of the..."/>
Celiac Disease Screening Program to Improve Awareness, Education and Diagnosis Nationwide
UnitedHealth Group, are taking immediate action to help people in Iowa who may be affected by the recent flooding. This includes assisting health plan participants who may need to make alternate..."/>
UnitedHealthcare and Optum Support People Affected by Floods in Iowa
NeuroMetrix, Inc. announced that Frank McGillin, Senior Vice President and General Manger, Consumer, will participate in a panel discussion on the THE DIGITAL HEALTHCARE REVOLUTION at the Wearable Technology Show in Santa Clara, CA on October 5 th. McGillin joins other industry leaders on the panel including Mark Prince, VP Consumer, Withings; Christine Lemke, Co-Founder& President, Evidation Health; and Manish Shah, CEO& Co-Founder, PeerWell."/>
NeuroMetrix Announces Frank McGillin Will Speak at the 2016 Wearable Technology Show
OurVetSuccess Launches 2016 Power Triumph Games
Molina Healthcare, Inc. today announced that it will report its earnings for the third quarter ended September 30, 2016, after the market closes on Thursday, October 27, 2016. The Company’ s management will host a conference call and webcast to discuss the earnings release at 5:00 p.m. Eastern time on the same day.. The number to call for the interactive teleconference is 231-2903. A telephonic replay of the conference call will be available from..."/>
Molina Healthcare Announces Third Quarter 2016 Earnings Release and Conference Call Date
Cannabis Science, Inc., a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce Cannabis Science launches new medicinal product lines for self-medicating patients via legal dispensaries and delivery within the State of California. The new CBIS medicinal product lines are being released based on patient usage data and general public opinion. The Company works with leading experts in drug development, medicinal..."/>
Cannabis Science Launches New Medicinal Product Line in Legal Dispensaries Within the State of California for Self-Medicating Patients
Bionor Pharma ASA. Following these transactions and issuance of the new shares in the Rights Offering Lars Høie holds 121,453,370 shares, equalling 8.76% of the then issued share capital. Lars Høie further owns 15,253,370 warrants in the Company."/>
Bionor Pharma ASA - Mandatory notification of trade - Lars Høie
Teladoc’ s industry leadership and continued expansion. LEWISVILLE, Texas---- Teladoc, Inc., the nation’ s leading provider of telehealth services, today announced that Mark Hirschhorn has been appointed to the newly created role of chief operating officer, while continuing to serve as the company’ s chief financial officer. The new role, and expansion of Mr."/>
Teladoc Names Hirschhorn Chief Operating Officer

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology669 Articles
Consumer Discretionary589 Articles
Financials405 Articles
Industrials377 Articles
Health Care349 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.